Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

QMSR In Action: FDA's Koven Warning Letter Flags Supplier Management And Design ...

5 August 2026 · By · Wire by Fusion42

Published

5 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at insights.citeline.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

The FDA issued a warning letter to Koven citing failures in supplier management and design change controls under Quality Management System Regulation (QMSR) requirements, highlighting areas of non-compliance relevant to medical device manufacturers.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You must tighten your supplier oversight and design control processes immediately to avoid FDA warning letters that could block market access. Compliance gaps now carry real risk for product delays and regulatory actions in US medtech.

◆ Coverage

1 source · 5 Aug 2026

◆ Related on Wire

◆ Topics

MedtechFDAwarning-lettersupplier-managementdesign-changecomplianceQMSR